Patents by Inventor Chiara Soncini

Chiara Soncini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a kinase inhibitor for the treatment of particular resistant tumors
    Patent number: 8084455
    Abstract: The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: December 27, 2011
    Assignee: Nerviano Medical Sciences S.r.l.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Juergen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
  • Use of a kinase inhibitor for the treatment of particular resistant tumors
    Patent number: 7803829
    Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: September 28, 2010
    Assignee: Nerviano Medical Sciences S.r.l.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Jurgen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
  • Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors
    Publication number: 20100035876
    Abstract: The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Application
    Filed: March 29, 2007
    Publication date: February 11, 2010
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Juergen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
  • USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS
    Publication number: 20100022532
    Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.
    Type: Application
    Filed: March 29, 2007
    Publication date: January 28, 2010
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Daniele Fancelli, Antonella Isacchi, Michele Modugno, Jurgen Moll, Luisa Rusconi, Chiara Soncini, Rosita Lupi
  • Substituted benzopyranones as telomerase inhibitors
    Publication number: 20040063665
    Abstract: The present invention relates to benzopyranone derivative, to methods for treating telomerase-modulated diseases, in particular cancers, with said derivatives, to a process for their preparation, to their use as medicaments and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 16, 2003
    Publication date: April 1, 2004
    Inventors: Alberto Bargiotti, Luisella Bonomini, Maria Menichincheri, Jurgen Moll, Paolo Polucci, Chiara Soncini, Ermes Vanotti
  • Substituted benzopyranones as telomerase inhibitors
    Publication number: 20020160983
    Abstract: The present invention relates to benzopyranone derivatives, to methods for treating telomerase-modulated diseases, in particular cancers, with said derivatives, to a process for their preparation, to their use as medicaments and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 16, 2001
    Publication date: October 31, 2002
    Inventors: Alberto Bargiotti, Luisella Bonomini, Maria Menichincheri, Jurgen Moll, Paolo Polucci, Chiara Soncini, Ermes Vanotti